CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...
Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international ...
That raises the stakes for a second area of Moderna’s research. In a partnership with Merck, it’s been using its mRNA ...
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it ...
Moderna, Inc. (NASDAQ:MRNA) is among the stocks in focus as Jim Cramer reviewed the S&P 500’s top performers and the Nasdaq 100’s biggest laggards for the first quarter. Cramer highlighted the bullish ...
Add Yahoo as a preferred source to see more of our stories on Google. Moderna said the FDA's refusal was inconsistent with previous feedback from the agency. - Graham Hughes/Bloomberg/Getty Images The ...
Expects pivotal trial data readouts in oncology, rare disease and infectious disease in 2026 CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced ...
March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing ...
In high-risk melanoma patients who had undergone complete tumor removal, adding Moderna's mRNA-4157 to Keytruda reduced the risk of recurrence or death by 49% versus Keytruda alone. The combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results